Lonoctocog alfa clinical trials
Also written CSL627 and rVIII-SingleChain.
How each study uses lonoctocog alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 25 May 2016 · Afstyla · BLA 125591 (FDA, Purple Book)
- European Union
- 4 Jan 2017 · Afstyla · EMEA/H/C/004075 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lonoctocog alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedPhase 3CSL BehringNCT06738485Written as Recombinant single-chain factor VIII (rVIII-SingleChain)
- An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia ACompletedPhase 3CSL BehringNCT02172950Written as rVIII-SingleChain
- Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia ACompletedPhase 3CSL BehringNCT02093897Written as rVIII-SingleChain
- An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia ACompletedPhase 2/3CSL BehringNCT01486927Written as rVIII-SingleChain
Codes
What other systems call lonoctocog alfa · ClinicalTrials.gg INT018264
- UNII (FDA) VQ723R7O8RLONOCTOCOG ALFAOne source FDA
- RxNorm 1796377One source FDA
- NCI Thesaurus C170127Lonoctocog AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VQ723R7O8R | LONOCTOCOG ALFA | One source FDA |
| RxNorm | 1796377 | — | One source FDA |
| NCI Thesaurus | C170127 | Lonoctocog Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.